

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

RESIGNATION AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board wish to announce that with effect from 15 August 2011, Mr. Shi has resigned as an independent non-executive Director and member of audit committee and remuneration committee of the Company.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board further announces that with effect from 15 August 2011, Ms. Fu has been appointed as an independent non-executive Director and member of audit committee and remuneration committee of the Company. The proposed appointment of Ms. Fu will be subject to shareholders' approval in the forthcoming special general meeting.

* *For identification purpose only*

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

The board of directors (the “Board”) of Shandong Weigao Group Medical Polymer Company Limited (the “Company”) announces that Mr. Shi Huan (“Mr. Shi”) has resigned as an independent non-executive director, a member of audit committee and a member of remuneration committee of the Company with effect from 15 August 2011 due to his retirement. Mr. Shi has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the shareholders of the Company in respect of his resignation.

The Board would like to take this opportunity to thank Mr. Shi for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, MEMBER OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

The Board further announces that, Ms. Fu Mingzhong (付明仲) (“Ms. Fu”) has been appointed as an independent non-executive director, a member of the audit committee and a member of remuneration committee of the Company subject to the approval by the shareholders of the Company at the forthcoming special general meeting which will be held at 9:00 a.m. on 10 October 2011. A circular containing details of the proposed appointment of Ms. Fu and a notice of the special general meeting is expected to be despatched to the shareholders as soon as practicable.

Ms. Fu

Ms. Fu, aged 61, senior economist and associate chief pharmacist and has over 40 years of working experience, particular in the area of management experience in the pharmaceutical and healthcare products industry. Ms. Fu obtained a master’s degree in engineering from the Harbin Institute of Technology in March 1995.

Ms. Fu was previously a workshop director, the head of the quality control office, the office head and the vice factory manager of The Third Harbin Pharmaceutical Factory from June 1972 to March 1999. Ms. Fu was a director of Harbin City Pharmaceutical Group and the general manager of Harbin Pharmaceutical Company Limited from March 1992 to December 1997. She was also a deputy general manager of China Medicines Group (中國醫藥(集團)公司) (currently known as China National Pharmaceutical Group (國藥集團)) from December 1997 to January 1999 and she was a director of China Medicines Group Corporation from January 1999 to July 2009 respectively. Ms. Fu was the executive deputy general manager of China National Pharmaceutical industry Corporation (中國醫藥工業公司) from January 1999 to January 2001. Ms. Fu was the chairman of National Medicines Company Limited (國藥集團藥業股份有限公司), (a company listed on the Shanghai Stock Exchange) from February 2001 to April 2008. Ms. Fu has been a director of Shenzhen Accord Pharmaceutical Company Ltd. (深圳一致藥業有限公司) (a company listed on the Shenzhen Stock Exchange) since April 2008 and was the chairman from April 2008 to December 2008. Ms. Fu has also been a director of Sinopharm Industrial Investment Co., Ltd. (國藥產業投資有限公司) from July 2008 to December 2010. Ms. Fu was the general manager, duty chairman and director of Sinopharm Group Co. Ltd., (國藥控股有限公司), (a company listed on the Hong Kong Stock Exchange) during the period from February 2006 to December 2009, and December 2009 to January 2011 respectively.

Ms. Fu is currently the chairman of China Association of Pharmaceutical Commerce and a member of the Thirteenth Shanghai Municipal People's Congress. Save as disclosed above, Ms. Fu did not hold any positions in the Company or any of its subsidiaries and did not hold any directorships in any other listed companies on the Stock Exchange and any other stock exchange in the three years preceding the date of this announcement.

The Company will enter into a service contract with Ms. Fu for a term of 3 years with effect from the date of the appointment. Her remuneration is fixed at RMB72,000 per annum, which is determined by the Board with reference to her duties and responsibilities within the Company and the prevailing market conditions. Save as director's remuneration disclosed herein, Ms. Fu is not entitled to any other benefits. Ms. Fu had not previously held or currently holds any position in the Company or its subsidiaries and he does not have any relationship with any directors, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules")).

As at the date of this announcement, Ms. Fu is not connected with any directors, chief executive, substantial shareholders or controlling shareholders of the Company (within the meaning of the Listing Rules). As at the date of this announcement, Ms. Fu does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters about the appointment of Ms. Fu as an independent non executive which are required to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the shareholders of the Company.

By order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Chen Xue Li
Chairman

Weihai, Shandong, the PRC

15 August 2011

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (*Executive Director*)
Mr. Miao Yan Guo (*Executive Director*)
Mr. Wang Yi (*Executive Director*)
Mr. Wang Zhi Fan (*Executive Director*)
Mr. Wu Chuan Ming (*Executive Director*)
Mr. Chen Xue Li (*Non-executive Director*)
Mrs. Zhou Shu Hua (*Non-executive Director*)
Mr. Jean-Luc Butel (*Non-executive Director*)
Mr. Li Bing Yung (*Non-executive Director*)
Mr. Luan Jian Ping (*Independent non-executive Director*)
Mr. Li Jia Miao (*Independent non-executive Director*)
Mr. Lo Wai Hung (*Independent non-executive Director*)